|Day Low/High||177.17 / 186.50|
|52 Wk Low/High||6.26 / 189.40|
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
Let's look at the stocks that will get crushed and that you can't touch right now.
The company has worked on two previous coronavirus vaccines as well as an Ebola vaccine.
We can't wait for a vaccine, but we can follow logical guidelines for staying as safe as possible, helping us avoid another Great Depression.
Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.
It's not often you have both overnight and intraday gap risk, so be aware, and good luck out there.
Check out just a few of the year-to-date moves coming into Thursday on 8 companies you've never heard of before the last week or two.
As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.
Stocks move cautiously higher as investors wait for direction from a number of market-churning events tomorrow.
"Such ingratitude, after all the times I saved your life." -- Blondie, THE GOOD THE BAD THE UGLY Let's run down the good, the bad and the ugly in today's market so far: THE GOOD Bonds are trading better today. The 10- and 30-year bond yields are dow...
I have followed Novavax for several years. After yesterday's market close the company announced the results of their Phase Three trial for a respiratory-virus drug. NVAX missed its goal, and the shares are trading down by about 80% ($8.40 to $1) i...
Another strong market day. The issue of taxes was front and center today. Here are some of my takes: My Take on Corporate Taxes Man Up, Allergan Shareholders Who Loses in Pfizer/Allergan Deal's Demise? I remain manifestly bearish, in the belief ...
The iShares Nasdaq Biotechnology ETF (IBB) has tumbled from nearly $400 a share early last summer to around $240 at last check, so I'm taking advantage of today's market schmeissing to purchase a small position in a biotech (biowreck?). I'm buying a...
Jim Cramer talks oil, Citigroup, burger joints and biotechs.
However, utilities and some technology names bucked the trend.